Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 39Lung Neoplasms 38Squamous Cell Carcinoma of Head and Neck 23Uterine Cervical Neoplasms 18Head and Neck Neoplasms 17Unspecified Adult Solid Tumor, Protocol Specific 13Central Nervous System Neoplasms 13Stomach Neoplasms 12Mesothelioma, Malignant 12Neuroblastoma 11Oropharyngeal Neoplasms 10Lymphoma 10Esophageal Neoplasms 10Ovarian Neoplasms 9Carcinoma, Ovarian Epithelial 9Urinary Bladder Neoplasms 8Adenocarcinoma of Lung 8Testicular Neoplasms 7Mouth Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Laryngeal Neoplasms 7Testicular Germ Cell Tumor 6Lymphoma, Large-Cell, Immunoblastic 6Carcinoma 6Astrocytoma 6Teratoma 5Small Cell Lung Carcinoma 5Peritoneal Neoplasms 5Oligodendroglioma 5

Interventions

molibresib 1etoposide phosphate 1Platinum 1Etoposide 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Metastatic NUT Carcinoma × Cisplatin × Clear all
NCT04116359 2020-09-28

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Withdrawn

Metastatic NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡